Post-earnings recap
Reported
Thu, Mar 8, 2018
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
50%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
CRISPR Therapeutics did not report any earnings or revenue figures, which is typical for a company in its early stages. Despite this, the stock rose by 4.29%, likely driven by investor optimism about the company's ongoing research and potential in the gene-editing space. The lack of guidance suggests uncertainty, but the market appears to be confident in the company's future prospects.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.00 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Management emphasized their commitment to research and development. They did not provide specific financial metrics or guidance for future performance.
Management did not provide specific financial guidance for the upcoming quarters.
The focus remains on advancing their pipeline of gene-editing therapies.